“If You Own Too Much Tech, You’re Going To Be Slaughtered.” Cramer Urges Investors To Take Profits

Jim Cramer, host of Mad Money, used his Tuesday morning appearance on CNBC’s “Squawk on the Street” on July 21, 2026 to fire a warning shot at investors who have ridden the AI trade to fresh highs and never taken a chip off the table. His message was blunt: “Because if you own too much tech, you’re going to be slaughtered. And you won’t even know what hit you. For the moment, it’s time to go to other sectors that can make you money without the volatility.”

With futures pointing higher on renewed semiconductor strength, Cramer wants investors to lean against the crowd and rotate proceeds into groups that have lagged the AI melt-up. The playbook: financials and healthcare, where valuations are cleaner and earnings power is showing up in results from banks that just reported.

The Discipline: Take Off Half When a Group Goes Red Hot

Cramer’s rotation call is rooted in position sizing, not a top call on tech. “When you have a group that is red hot, you take off half. You have to be disciplined, and the reason why you have to be disciplined is because a lot of this last run, the parabolic move, is not cured by a 20% to 30% decline because the stock went up more than that.”

Micron Technology (NASDAQ:MU | MU Price Prediction) is Exhibit A. Cramer suggested a few weeks ago that investors sell half of Micron, and the numbers explain why. Shares are up 240.36% year to date and 758.78% over the past year. Fiscal Q3 2026 revenue landed at $41.456 billion, a 17.60% beat, with non-GAAP EPS of $25.11 versus $20.28 expected and GAAP gross margin expanding to 84.6% from 37.7% a year earlier. The fundamentals are real; the move is parabolic. Polymarket contracts currently price a 0.74 probability that Micron closes lower on July 22.

Where Cramer Sees Value: Banks at 12 to 15 Times Earnings

The sector composition is already tilting. Among the top ten DOW names year to date, eight are either healthcare or financials. The July 14 bank earnings gave the rotation fresh fuel.

JPMorgan Chase (NYSE:JPM) posted Q2 EPS of $7.70 versus $5.80 expected on $57.35 billion in revenue, and authorized a fresh $50 billion buyback. Cramer’s take on Jamie Dimon: “You can buy his stock for 15 times earnings. It’s one of the brightest guys in the world. Jamie and his team is filled with brilliant people. 15 times. I’ll take it.” Shares are up 8.65% YTD.

Bank of America (NYSE:BAC) trades at 14 times earnings, delivered a fifth consecutive EPS beat at $1.21, and is up 13.34% YTD. Wells Fargo trades at 12 times earnings and remains -4.84% YTD, the kind of laggard Cramer is willing to buy while others chase memory chips.

Healthcare: Lilly the GLP-1 Winner

Cramer’s second lane is pharma, and he wants the winner of the GLP-1 war. “I will say, you know what? Let me go and buy some Lilly into the Novo Nordisk weakness.”

Eli Lilly (NYSE:LLY) reported Q1 EPS of $8.55 versus $6.79 expected and revenue of $19.80 billion, up 55.5% YoY, then raised 2026 guidance to $82.0-$85.0 billion. Mounjaro alone did $8.66 billion, up 125%. Novo Nordisk, by contrast, is down 20.46% over the past year and guided full-year adjusted sales to a decline of 4% to 12% at constant currency.

The Takeaway

Cramer’s message is about discipline. He wants investors to recognize when a move has run past what any normal pullback could fix, trim into strength, and redeploy where earnings are compounding at reasonable multiples. Banks reporting record quarters at 12 to 15 times earnings and a pharma leader raising guidance mid-year give him a place to put the profits. The discipline is the point.

Contact [email protected] for any questions or corrections.